TY  - JOUR
AU  - Davis, Nicole M.
AU  - Sokolosky, Melissa
AU  - Stadelman, Kristin
AU  - Abrams, Stephen L.
AU  - Libra, Massimo
AU  - Candido, Saverio
AU  - Nicoletti, Ferdinando
AU  - Polesel, Jerry
AU  - Maestro, Roberta
AU  - D'Assoro, Antonino
AU  - Drobot, Lyudmyla
AU  - Rakus, Dariusz
AU  - Gizak, Agnieszka
AU  - Laidler, Piotr
AU  - Dulinska-Litewka, Joanna
AU  - Basecke, Joerg
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Montalto, Giuseppe
AU  - Cervello, Melchiorre
AU  - Fitzgerald, Timothy L.
AU  - Demidenko, Zoya N.
AU  - Martelli, Alberto M.
AU  - Cocco, Lucio
AU  - Steelman, Linda S.
AU  - McCubrey, James A.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2188
AB  - The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in
   malignant transformation, prevention of apoptosis, drug resistance and
   metastasis. The expression of this pathway is frequently altered in
   breast cancer due to mutations at or aberrant expression of: HER2,
   ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other
   oncogenes and tumor suppressor genes. In some breast cancer cases,
   mutations at certain components of this pathway (e.g., PIK3CA) are
   associated with a better prognosis than breast cancers lacking these
   mutations. The expression of this pathway and upstream HER2 has been
   associated with breast cancer initiating cells (CICs) and in some cases
   resistance to treatment. The anti-diabetes drug metformin can suppress
   the growth of breast CICs and herceptin-resistant HER2+ cells. This
   review will discuss the importance of the
   EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but
   will also include relevant examples from other cancer types. The
   targeting of this pathway will be discussed as well as clinical trials
   with novel small molecule inhibitors. The targeting of the hormone
   receptor, HER2 and EGFR1 in breast cancer will be reviewed in
   association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3
   pathway.
T2  - Oncotarget
T1  - Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention
IS  - 13
VL  - 5
DO  - 10.18632/oncotarget.2209
SP  - 4603
EP  - 4650
ER  - 

@article{
author = "Davis, Nicole M. and Sokolosky, Melissa and Stadelman, Kristin and Abrams, Stephen L. and Libra, Massimo and Candido, Saverio and Nicoletti, Ferdinando and Polesel, Jerry and Maestro, Roberta and D'Assoro, Antonino and Drobot, Lyudmyla and Rakus, Dariusz and Gizak, Agnieszka and Laidler, Piotr and Dulinska-Litewka, Joanna and Basecke, Joerg and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Montalto, Giuseppe and Cervello, Melchiorre and Fitzgerald, Timothy L. and Demidenko, Zoya N. and Martelli, Alberto M. and Cocco, Lucio and Steelman, Linda S. and McCubrey, James A.",
year = "2014",
abstract = "The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in
   malignant transformation, prevention of apoptosis, drug resistance and
   metastasis. The expression of this pathway is frequently altered in
   breast cancer due to mutations at or aberrant expression of: HER2,
   ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other
   oncogenes and tumor suppressor genes. In some breast cancer cases,
   mutations at certain components of this pathway (e.g., PIK3CA) are
   associated with a better prognosis than breast cancers lacking these
   mutations. The expression of this pathway and upstream HER2 has been
   associated with breast cancer initiating cells (CICs) and in some cases
   resistance to treatment. The anti-diabetes drug metformin can suppress
   the growth of breast CICs and herceptin-resistant HER2+ cells. This
   review will discuss the importance of the
   EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but
   will also include relevant examples from other cancer types. The
   targeting of this pathway will be discussed as well as clinical trials
   with novel small molecule inhibitors. The targeting of the hormone
   receptor, HER2 and EGFR1 in breast cancer will be reviewed in
   association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3
   pathway.",
journal = "Oncotarget",
title = "Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention",
number = "13",
volume = "5",
doi = "10.18632/oncotarget.2209",
pages = "4603-4650"
}

Davis, N. M., Sokolosky, M., Stadelman, K., Abrams, S. L., Libra, M., Candido, S., Nicoletti, F., Polesel, J., Maestro, R., D'Assoro, A., Drobot, L., Rakus, D., Gizak, A., Laidler, P., Dulinska-Litewka, J., Basecke, J., Mijatović, S., Maksimović-Ivanić, D., Montalto, G., Cervello, M., Fitzgerald, T. L., Demidenko, Z. N., Martelli, A. M., Cocco, L., Steelman, L. S.,& McCubrey, J. A.. (2014). Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention. in Oncotarget, 5(13), 4603-4650.
https://doi.org/10.18632/oncotarget.2209

Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, Mijatović S, Maksimović-Ivanić D, Montalto G, Cervello M, Fitzgerald TL, Demidenko ZN, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention. in Oncotarget. 2014;5(13):4603-4650.
doi:10.18632/oncotarget.2209 .

Davis, Nicole M., Sokolosky, Melissa, Stadelman, Kristin, Abrams, Stephen L., Libra, Massimo, Candido, Saverio, Nicoletti, Ferdinando, Polesel, Jerry, Maestro, Roberta, D'Assoro, Antonino, Drobot, Lyudmyla, Rakus, Dariusz, Gizak, Agnieszka, Laidler, Piotr, Dulinska-Litewka, Joanna, Basecke, Joerg, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Montalto, Giuseppe, Cervello, Melchiorre, Fitzgerald, Timothy L., Demidenko, Zoya N., Martelli, Alberto M., Cocco, Lucio, Steelman, Linda S., McCubrey, James A., "Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention" in Oncotarget, 5, no. 13 (2014):4603-4650,
https://doi.org/10.18632/oncotarget.2209 . .

TY  - CONF
AU  - McCubrey, James A.
AU  - Chappell, William H.
AU  - Abrams, Stephen L.
AU  - Davis, Nicole
AU  - Libra, Massimo
AU  - Candido, Saverio
AU  - Nicoletti, Ferdinando
AU  - Polesel, Jerry
AU  - Talamini, Renato
AU  - Maestro, Roberta
AU  - Martelli, Alberto M.
AU  - Cervello, Melchiorre
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Steelman, Linda S.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2277
C3  - International Journal of Molecular Medicine
T1  - Suppressing prostate cancer by targeting NGAL
IS  - 1
VL  - 34
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_2277
ER  - 

@conference{
author = "McCubrey, James A. and Chappell, William H. and Abrams, Stephen L. and Davis, Nicole and Libra, Massimo and Candido, Saverio and Nicoletti, Ferdinando and Polesel, Jerry and Talamini, Renato and Maestro, Roberta and Martelli, Alberto M. and Cervello, Melchiorre and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Steelman, Linda S.",
year = "2014",
journal = "International Journal of Molecular Medicine",
title = "Suppressing prostate cancer by targeting NGAL",
number = "1",
volume = "34",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_2277"
}

McCubrey, J. A., Chappell, W. H., Abrams, S. L., Davis, N., Libra, M., Candido, S., Nicoletti, F., Polesel, J., Talamini, R., Maestro, R., Martelli, A. M., Cervello, M., Maksimović-Ivanić, D., Mijatović, S.,& Steelman, L. S.. (2014). Suppressing prostate cancer by targeting NGAL. in International Journal of Molecular Medicine, 34(1).
https://hdl.handle.net/21.15107/rcub_ibiss_2277

McCubrey JA, Chappell WH, Abrams SL, Davis N, Libra M, Candido S, Nicoletti F, Polesel J, Talamini R, Maestro R, Martelli AM, Cervello M, Maksimović-Ivanić D, Mijatović S, Steelman LS. Suppressing prostate cancer by targeting NGAL. in International Journal of Molecular Medicine. 2014;34(1).
https://hdl.handle.net/21.15107/rcub_ibiss_2277 .

McCubrey, James A., Chappell, William H., Abrams, Stephen L., Davis, Nicole, Libra, Massimo, Candido, Saverio, Nicoletti, Ferdinando, Polesel, Jerry, Talamini, Renato, Maestro, Roberta, Martelli, Alberto M., Cervello, Melchiorre, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Steelman, Linda S., "Suppressing prostate cancer by targeting NGAL" in International Journal of Molecular Medicine, 34, no. 1 (2014),
https://hdl.handle.net/21.15107/rcub_ibiss_2277 .

TY  - JOUR
AU  - McCubrey, James A
AU  - Steelman, Linda S
AU  - Chappell, William H
AU  - Sun, Lin
AU  - Davis, Nicole M
AU  - Abrams, Stephen L
AU  - Franklin, Richard A
AU  - Cocco, Lucio
AU  - Evangelisti, Camilla
AU  - Chiarini, Francesca
AU  - Martelli, Alberto M
AU  - Libra, Massimo
AU  - Candido, Saverio
AU  - Ligresti, Giovanni
AU  - Malaponte, Graziella
AU  - Mazzarino, Maria C
AU  - Fagone, Paolo
AU  - Donia, Marco
AU  - Nicoletti, Ferdinando
AU  - Polesel, Jerry
AU  - Talamini, Renato
AU  - Baesecke, Joerg
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Milella, Michele
AU  - Tafuri, Agostino
AU  - Dulinska-Litewka, Joanna
AU  - Laidler, Piotr
AU  - D'Assoro, Antonio B
AU  - Drobot, Lyudmyla
AU  - Umezawa, Kazuo
AU  - Montalto, Giuseppe
AU  - Cervello, Melchiorre
AU  - Demidenko, Zoya N
PY  - 2012
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/1071
AB  - Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.
T2  - Oncotarget
T1  - Advances in Targeting Signal Transduction Pathways
IS  - 12
VL  - 3
SP  - 69
EP  - 1521
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_1071
ER  - 

@article{
author = "McCubrey, James A and Steelman, Linda S and Chappell, William H and Sun, Lin and Davis, Nicole M and Abrams, Stephen L and Franklin, Richard A and Cocco, Lucio and Evangelisti, Camilla and Chiarini, Francesca and Martelli, Alberto M and Libra, Massimo and Candido, Saverio and Ligresti, Giovanni and Malaponte, Graziella and Mazzarino, Maria C and Fagone, Paolo and Donia, Marco and Nicoletti, Ferdinando and Polesel, Jerry and Talamini, Renato and Baesecke, Joerg and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Milella, Michele and Tafuri, Agostino and Dulinska-Litewka, Joanna and Laidler, Piotr and D'Assoro, Antonio B and Drobot, Lyudmyla and Umezawa, Kazuo and Montalto, Giuseppe and Cervello, Melchiorre and Demidenko, Zoya N",
year = "2012",
abstract = "Over the past few years, significant advances have occurred in both our understanding of the complexity of signal transduction pathways as well as the isolation of specific inhibitors which target key components in those pathways. Furthermore critical information is being accrued regarding how genetic mutations can affect the sensitivity of various types of patients to targeted therapy. Finally, genetic mechanisms responsible for the development of resistance after targeted therapy are being discovered which may allow the creation of alternative therapies to overcome resistance. This review will discuss some of the highlights over the past few years on the roles of key signaling pathways in various diseases, the targeting of signal transduction pathways and the genetic mechanisms governing sensitivity and resistance to targeted therapies.",
journal = "Oncotarget",
title = "Advances in Targeting Signal Transduction Pathways",
number = "12",
volume = "3",
pages = "69-1521",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_1071"
}

McCubrey, J. A., Steelman, L. S., Chappell, W. H., Sun, L., Davis, N. M., Abrams, S. L., Franklin, R. A., Cocco, L., Evangelisti, C., Chiarini, F., Martelli, A. M., Libra, M., Candido, S., Ligresti, G., Malaponte, G., Mazzarino, M. C., Fagone, P., Donia, M., Nicoletti, F., Polesel, J., Talamini, R., Baesecke, J., Mijatović, S., Maksimović-Ivanić, D., Milella, M., Tafuri, A., Dulinska-Litewka, J., Laidler, P., D'Assoro, A. B., Drobot, L., Umezawa, K., Montalto, G., Cervello, M.,& Demidenko, Z. N.. (2012). Advances in Targeting Signal Transduction Pathways. in Oncotarget, 3(12), 69-1521.
https://hdl.handle.net/21.15107/rcub_ibiss_1071

McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Baesecke J, Mijatović S, Maksimović-Ivanić D, Milella M, Tafuri A, Dulinska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa K, Montalto G, Cervello M, Demidenko ZN. Advances in Targeting Signal Transduction Pathways. in Oncotarget. 2012;3(12):69-1521.
https://hdl.handle.net/21.15107/rcub_ibiss_1071 .

McCubrey, James A, Steelman, Linda S, Chappell, William H, Sun, Lin, Davis, Nicole M, Abrams, Stephen L, Franklin, Richard A, Cocco, Lucio, Evangelisti, Camilla, Chiarini, Francesca, Martelli, Alberto M, Libra, Massimo, Candido, Saverio, Ligresti, Giovanni, Malaponte, Graziella, Mazzarino, Maria C, Fagone, Paolo, Donia, Marco, Nicoletti, Ferdinando, Polesel, Jerry, Talamini, Renato, Baesecke, Joerg, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Milella, Michele, Tafuri, Agostino, Dulinska-Litewka, Joanna, Laidler, Piotr, D'Assoro, Antonio B, Drobot, Lyudmyla, Umezawa, Kazuo, Montalto, Giuseppe, Cervello, Melchiorre, Demidenko, Zoya N, "Advances in Targeting Signal Transduction Pathways" in Oncotarget, 3, no. 12 (2012):69-1521,
https://hdl.handle.net/21.15107/rcub_ibiss_1071 .

TY  - CONF
AU  - McCubrey, James A
AU  - Chappell, William H
AU  - Abrams, Stephen L
AU  - Martelli, Alberto M
AU  - Nicoletti, Ferdinando
AU  - Fagone, Paolo
AU  - Libra, Massimo
AU  - Cervello, Melchiorre
AU  - Maksimović-Ivanić, Danijela
AU  - Mijatović, Sanja
AU  - Polesel, Jerry
AU  - Talamini, Renato
AU  - Maestro, Roberta
AU  - Steelman, Linda S
PY  - 2012
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/1219
C3  - International Journal of Molecular Medicine
T1  - Role of NGAL (Lcn2) in prostate cancer invasion
IS  - null
VL  - 30
EP  - S25
UR  - https://hdl.handle.net/21.15107/rcub_ibiss_1219
ER  - 

@conference{
author = "McCubrey, James A and Chappell, William H and Abrams, Stephen L and Martelli, Alberto M and Nicoletti, Ferdinando and Fagone, Paolo and Libra, Massimo and Cervello, Melchiorre and Maksimović-Ivanić, Danijela and Mijatović, Sanja and Polesel, Jerry and Talamini, Renato and Maestro, Roberta and Steelman, Linda S",
year = "2012",
journal = "International Journal of Molecular Medicine",
title = "Role of NGAL (Lcn2) in prostate cancer invasion",
number = "null",
volume = "30",
pages = "S25",
url = "https://hdl.handle.net/21.15107/rcub_ibiss_1219"
}

McCubrey, J. A., Chappell, W. H., Abrams, S. L., Martelli, A. M., Nicoletti, F., Fagone, P., Libra, M., Cervello, M., Maksimović-Ivanić, D., Mijatović, S., Polesel, J., Talamini, R., Maestro, R.,& Steelman, L. S.. (2012). Role of NGAL (Lcn2) in prostate cancer invasion. in International Journal of Molecular Medicine, 30(null).
https://hdl.handle.net/21.15107/rcub_ibiss_1219

McCubrey JA, Chappell WH, Abrams SL, Martelli AM, Nicoletti F, Fagone P, Libra M, Cervello M, Maksimović-Ivanić D, Mijatović S, Polesel J, Talamini R, Maestro R, Steelman LS. Role of NGAL (Lcn2) in prostate cancer invasion. in International Journal of Molecular Medicine. 2012;30(null):null-S25.
https://hdl.handle.net/21.15107/rcub_ibiss_1219 .

McCubrey, James A, Chappell, William H, Abrams, Stephen L, Martelli, Alberto M, Nicoletti, Ferdinando, Fagone, Paolo, Libra, Massimo, Cervello, Melchiorre, Maksimović-Ivanić, Danijela, Mijatović, Sanja, Polesel, Jerry, Talamini, Renato, Maestro, Roberta, Steelman, Linda S, "Role of NGAL (Lcn2) in prostate cancer invasion" in International Journal of Molecular Medicine, 30, no. null (2012),
https://hdl.handle.net/21.15107/rcub_ibiss_1219 .